Overall impact
B (64)

Commentary

Vyant Bio is a strong overall performer. With a 'B' rating of 63.8 for overall impact (71st percentile compared to all companies), Vyant Bio ranks 45th out of 76 industry peers, behind IMAC, Enzo Biochem, Invitae and 41 others, and ahead of Ortho Clinical Diagnostics, T2 Biosystems, Fulgent Genetics and 28 others. On top material causes for Vyant Bio's industry (Healthcare Software & Services), Vyant Bio performs well in Reduced Waste (81.6 score), Reduced Use of tobacco (86.5) and Disease Eradication (86.1) and performs poorly in Quality Lifelong Education (1.5 score) and Decent, Safe Work Opportunities (39.7).
Impact
Cause VYNT
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
4
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Nj, United States
Share classes
VYNT
Description
Vyant Bio, Inc. is a biotechnology company that discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD), and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.
Material causes
Ethos considers the following causes material for Vyant Bio, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.